


Bernd Stowasser, MS, PhD

Head Global Public Private Partnerships and R&D Alliance
Management Germany, Strategy & Business Development, Sanofi

Core Member EFPIA Innovative Medicines Strategy Priority
Working Group

The Innovative Medicines Initiative (IMI) is the largest Public-Private Partnership (PPP) in the global healthcare sector

Partnership between EFPIA and the European Commission



Architecture and principles

- Research topics developed **by pharmaceutical companies**
- Companies invest **with own FTE**
- Public partner's selection is **highly competitive**
- IMI organization serves as **neutral platform**
- **Consensus-driven joint leadership** by EFPIA and public leader

Improve understanding of intracellular uptake and trafficking mechanisms of biologics

- Formulations for non-invasive delivery of peptide- and protein-based drugs constructed and characterized
- Sophisticated in vitro and in vivo models for the various barriers* established
- Potential novel targets for targeting the Blood-Brain-Barrier identified
- Identification and characterization of transport pathways across biological barriers and cell membranes ongoing

*Brain, air-blood, intestinal, skin

7 Pharma Companies:

- Sanofi (Coordinator)
- GSK
- AbbVie
- Boehringer Ingelheim
- Merck Serono
- Novo Nordisk
- Pfizer

15 Academic Partners & Biotech:

- Universiteit Utrecht
- Cardiff University
- Helmholtz-Zentrum für Infektionsforschung
- University of Copenhagen
- University of Oxford
- University of Helsinki
- Ludwig-Maximilians-Universität
- Universitet NTNU
- Stockholms Universitet
- Universität Wien
- Universität Zurich
- Universiteit Gent
- Universiteit Leiden
- Bioneer
- Pharmacoidea


IMI funding:	10.2 M€
Academia / Biotech cont.	3.2 M€
Pharma resources: :	16.6 M€
TOTAL PROJECT COST:	30 M€

Starting Date 1-11-2012
Duration : 60 Month

Upcoming IMI project on the Blood-Brain-Barrier (BBB)

Discovery and characterisation of blood-brain barrier targets and transport mechanisms for brain delivery of therapeutics to treat neurodegenerative & metabolic diseases

- Discovery and development of innovative and efficacious brain delivery systems
- Establishment and characterisation of BBB models with good predictability
- Identification of translational readouts closer to the pathogenesis of neurodegeneration
- In-depth understanding of the biology of the BBB and characterization of various transport mechanisms across the BBB



Capitalizing on the findings from the IMI COMPACT consortium, namely several potential new targets for brain delivery

7 Pharma Companies:

- Sanofi (Lead)
- Pfizer
- GSK
- Janssen
- Novartis
- NovoNordisk
- Fujifilm

Total Budget:	18 Mio€
Starting Date	Q2 2018
Duration	60 Month

Benefits for stakeholders of public-private partnerships

A Typical IMI Consortium



Benefits for academia/hospitals

- Joining and shaping vibrant, collaborative and translational health innovation ecosystem
- Fostering validation, standardization, joint protocols and reproducibility of results
- Gaining development expertise
- Advancing basic research towards application and translation into benefits for patients

Benefits for pharmaceutical companies

- Addressing bottlenecks in drug discovery
- Accessing enhanced knowledge and innovative technology
- Sharing and pooling data, knowledge, skills and risks
- Building consensus
- Paving the way for future collaborations

Benefits for SME

- Building partnerships, reputation and visibility
- Perfecting innovative services and products - and pitch them.
- Accelerating business expansion